Today’s Top Stories in Diabetes News!

Heart rate recovery predicts diabetes risk

BY REGINA SCHAFFER: In healthy adults, each 10 beats per minute decrement in attenuated heart rate recovery increases the risk for incident diabetes by 29%, independent of traditional cardiovascular disease risk factors, such as age, BMI or fasting blood glucose, according to a meta-analysis.

Heart rate recovery — the reduction in heart rate from the peak rate attained during exercise to the rate attained in the minutes after the cessation of exercise — has been recognized as a noninvasive measure of autonomic function, Shanhu Qiu, MD, of the department of endocrinology at Southeast University School of Medicine in Nanjing, China, and colleagues wrote in the study background. Recently, evidence has suggested that attenuated heart rate recovery may carry prognostic power in predicting the risk for diabetes, they wrote. (read more)


Rare tumor may point the way to diabetes treatment

BY SERENA GORDON: A rare, benign tumor that grows in the pancreas may give doctors the tools they need to help people with diabetes make more insulin.

These tumors are called insulinomas because they secrete the hormone insulin in excessive amounts. People with diabetes don’t have enough insulin to cover their bodies’ basic needs for the hormone.

The researchers thought by mapping the genetic makeup of insulinoma tumors, they might come up with the genomic recipe for regenerating the beta cells that produce insulin. And if they could use that “recipe” to make a drug that would trigger the body to make insulin, they could treat — or possibly even reverse — diabetes. (read more)

US FDA rejects Intarcia’s diabetes treatment implant

BY GARETH MACDONALD: The US FDA has rejected an implantable diabetes treatment developed by Intarcia Therapeutics, Inc. and asked for more information about how the drug-device combination therapy is made. (read more)

The FDA just approved a new form of insulin

BY LYDIA RAMSEY: The Food and Drug Administration on Friday approved Novo Nordisk’s fast-acting insulin to treat diabetes.

The product, known as Fiasp, is designed to help diabetics control post-meal spikes in blood sugar. It is already approved in Canada and Europe. (read more)

Fecal transplant success for diabetes might depend on the recipient’s gut microbes

BY CELL PRESS: “We have now shown that you can categorize people based on their fecal samples,” says senior author Max Nieuwdorp of the Department of Internal and Vascular Medicine at the University of Amsterdam. “This allows us to classify diseases with more sensitivity.”

Six weeks after participants received fecal material from a lean donor, half of them saw an improvement in insulin sensitivity, whereas the other half saw no change. “The fifty-fifty responder-to-non-responder rate surprised me,” says Nieuwdorp. “I thought we would have fewer people respond to the transplant.” The researchers then compared the pre-treatment microbiota of both groups and found that the non-responders were the ones who started off with less bacterial diversity. (read more)